MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Supplier Stories for the Week of December 1

Here’s what was new in the world of medical device suppliers during the week of December 1.

  • Biomerics LLC, a contract manufacturer for the interventional medical device market, and ATL Technology LLC have mutually agreed to dissolve their joint venture, Biomerics ATL LLC, the companies reported in a news release. Biomerics has purchased ATL Technology’s interests in the joint venture and will rename the business unit Biomerics CRI (BCRI), bringing its operations up to seven business units with more than 1300 employees.

    The joint venture had begun in 2018 with the acquisition of assets from Catheter Research Inc. (CRI Medical) and its facilities in Indiana and Costa Rica. CRI had served the medical device fluid management market. Biomerics's purchase of ATL’s ownership will enable it to expand its presence into Costa Rica and its relationship with these customers. It will also increase the company's capabilities, including extrusion, injection molding, high-volume cleanroom assembly, kitting, and packaging services.

    “Our expansion of operations in Costa Rica is strategic,” stated Travis Sessions, CEO of Biomerics, in a news release. “We see great potential in these assets providing high volume assembly operations. We recently expanded the facility with a new 3,700-sq-ft cleanroom and are planning an additional 20,000-sq-ft expansion in 2021.”

    Added Craig England, who now serves as the new business unit’s president: “It has been an honor working with both Biomerics and ATL Technology over the last 18 months. The new strategy will add to the momentum of the organization and prepare us for great things down the road as we unlock the synergies of Biomerics.”

    Anthony Amador is now general manager of the Costa Rica facility. All employees have been retained as part of the realignment and will continue operations as usual under the new business entity, it was reported in the release.

    Biomerics has ISO-13485:2016 compliant operations in Minnesota, Utah, Texas, Connecticut, Indiana, and Costa Rica.

    [Image courtesy of BIOMERICS]

  • In November 2019, Plastic Molding Manufacturing announced its acquisition of Phillips-Moldex Company. “It has been our goal for many years to keep manufacturing in the United States and this acquisition demonstrates our objective to be a national plastic molder with a local service to our customers,” said George E. Danis, CEO of Plastic Molding Manufacturing, in a news release.

    Founded in 1958, Phillips-Moldex is an ISO 9001:2015/IATF16949-2016 certified plastic injection molder serving the medical, electronics, automotive, and industrial markets. It runs 24 hours a day, 5 days a week, with 22 injection presses ranging from 20-250 tons and offers in-house tool building and expertise in automation and engineering.

    “We work to continuously challenge ourselves and focus on our journey to make our customers not only happy but to exceed their expectations," said Danis in the release. "Our goal in acquiring other companies is to increase our support and capabilities for our customers across the country, so in return they will bring their manufacturing business back to the United States.”

    Plastic Molding Manufacturing is headquartered in Hudson, MA, and it runs locations in Berlin, CT; Lancaster, PA; and South Bend, IN. It also operates an ISO Class 8 certified cleanroom.

    Molding Business Services served as Plastic Molding Manufacturing's advisor for the transaction.

    [Image of George E. Danis, courtesy of PLASTIC MOLDING MANUFACTURING]

  • At Compamed 2019 DuPont highlighted its portfolio of silicone adhesives, elastomers, and specialty polymers for patient-centric applications such as wound and ostomy care and self-administered drug delivery devices. 

    “As the industry transitions to a proactive, well-care approach emphasizing active patient participation and care delivery in outpatient and home settings, DuPont is leveraging its materials, technical resources, and partnerships across the global value chain to drive the development of next-generation devices,” stated Jennifer Gemo, global strategic marketing leader, Healthcare at DuPont Transportation & Industrial, in a news release. “Our patient-centric technologies for enhancing comfort and effectiveness, such as soft, conformable silicone skin adhesives, and functional specialty polymers for smaller, less-invasive, self-administered drug delivery devices, help improve patient compliance. DuPont is committed to advancing the development of new wearables and self-care devices for better patient outcomes.” 

    For example, DuPont's Crastin SC193 polybutylene terephthalate-styrene acrylonitrile (PBT-SAN) resin can enable designers to develop functional, static-resistant components with longer-term load for injection pens and to ease the actuation of these devices while ensuring stability during the fabrication step, the company reported.  

    Its family of silicone skin adhesives offers a broad range of peel strengths for different device requirements and wear durations. For example, the company’s non-irritating soft skin adhesives (SSAs), featuring gentle adhesion and easy removal/repositioning, can be used for advanced wound care and for populations with vulnerable or delicate skin, such as infants and the elderly, it was reported. Pressure-sensitive adhesives (PSAs) with higher peel strength can be used for transdermal drug delivery patches and wearable monitors. 

    And at Medica 2019, DuPont highlighted a new connected wearable device concept, a wearable patch prototype designed by the Holst Center and manufactured by Pronat Medical, which combines DuPont Intexar soft, stretchable electronics and DuPont silicone SSAs to optimize skin conformability, breathability, and patient comfort. It is intended for measuring cardiovascular activity. 

    [Logo courtesy of DUPONT]

  • At Medica 2019, Avery Dennison Medical launched several products and official unveiled Avery Dennison Medical as the new unified brand for Vancive Medical Technologies and Finesse Medical Ltd. “For applications ranging from glucose monitors to ostomy appliances, each new material is designed for both optimal patient experience and manufacturability,” stated Deepak Prakash, senior director, global marketing, Avery Dennison Medical, in a news release. 

    The new products included:

    ● MED 5740, MED 5741, and MED 5742 single-coated adhesive materials designed for long-term, multi-week wear for applications such as glucose monitors, insulin pumps, activity trackers, electrocardiogram monitors, and other mobile health and wellness products. The materials are soft, conformable, and breathable.

    ● A new five-layer silicone foam border dressing for private labeling (shown above). Designed to manage moderate to high wound exudate, the breathable dressing features a PU foam and super-absorbent fiber composite pad.

    ● MED 5043 single-coated, soft, transparent PU film offering wound and surgical site visibility, conformability, breathability, and moisture resistance. It is compatible with ethylene oxide and gamma irradiation sterilization methods.

    ● MED 5710SI single-sided soft-skin silicone adhesive nonwoven material for advanced wound care dressings or as a cover tape for finished devices. 

    ● MED 5541H single-coated, transparent PU film designed for wound care, ostomy, and device fixation applications. Its integrated hydrocolloid formulation offers high fluid-handling capacity and remains intact upon saturation. 

    ● MED 5712SI single-sided soft-skin silicone adhesive nonwoven tape is water repellant. The nonwoven carrier features a fluorine coating to allow the tape to be self-wound without the need for a release liner.

    [Image courtesy of AVERY DENNISON MEDICAL] 

Daphne Allen

Daphne Allen is editor-in-chief of MD+DI. She previously served as executive editor of Pharmaceutical & Medical Packaging News, which serves as the pharmaceutical and medical device channel of Packaging Digest. Daphne has covered medical device manufacturing, packaging, labeling, and regulatory issues as well as pharmaceutical packaging and labeling for more than 20 years. She is also a member of the Institute of Packaging Professionals's Medical Device Packaging Technical Committee. Follow her on Twitter at @daphneallen.

 

500 characters remaining